Search

A recent study conducted by researchers at Kyungpook National University focused on the role of MTMR6 downregulation in contributing to cisplatin resistance in oral squamous cell carcinoma (OSCC). The research aimed to elucidate the molecular mechanisms underlying this resistance and found that modulating MTMR6 activity alters cisplatin resistance. The study suggests that assessing mRNA levels of MTMR6 and has-miR-544a in biopsy samples could help predict cisplatin responsiveness in OSCC patients. This research provides valuable insights into potential predictive markers for treatment outcomes in OSCC patients receiving cisplatin therapy. [Extracted from the article]

Researchers from Swansea University Medical School conducted a study on ovarian cancer, focusing on how cisplatin resistance impacts the formation of cancer spheroids and peritoneal invasion. The study utilized microscopy techniques and gene expression analysis to identify differences in biophysical properties and protein expression between cisplatin-resistant and parental spheroids. The findings suggest that altered protein expression in cisplatin-resistant spheroids may contribute to changes in metastatic progression, highlighting potential targets for therapeutic intervention. The research was published in Frontiers in Cell and Developmental Biology and can be accessed for further information. [Extracted from the article]

A recent study from Tehran University of Medical Sciences compared the efficacy of Photodynamic Therapy (PDT) with cisplatin therapy in treating cancer. The study found that cisplatin targets key cellular functions related to cancer development, while PDT intensifies its effects and reduces side effects. This research provides valuable insights into potential treatment options for cancer patients. [Extracted from the article]

A recent report from Central South University discusses the role of circRNF13 in oral cancer, highlighting its potential as a cancer biomarker. The study found that circRNF13 is associated with increased tumor grade and stage in oral cancer, promoting cancer cell proliferation and tumor growth while reducing sensitivity to cisplatin. This research sheds light on the mechanistic role of circRNAs in oral cancer and suggests circRNF13 as a potential therapeutic target. [Extracted from the article]

A recent study conducted at Yanbian University Hospital in Yanji, People's Republic of China, explored the synergistic effects of combining the STING agonist c-di-AMP and ginsenoside RG3 to reverse cisplatin resistance in gastric cancer cells. The research utilized various techniques to investigate the mechanisms and effects of this combination treatment, which significantly inhibited malignant behaviors and reversed drug resistance in gastric cancer. The study provides a theoretical foundation for potential clinical applications and highlights new therapeutic targets for future research in oncology. [Extracted from the article]

A recent study conducted by researchers at Macau University of Science & Technology compared the effectiveness of two different chemotherapy regimens, TPF and PF, combined with cisplatin concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma (LA-NPC). The study found that the TPF regimen resulted in significantly improved progression-free survival, overall survival, and locoregional recurrence-free survival compared to the PF regimen. However, the incidence of grade 3 or 4 neutropenia and diarrhea was higher in the TPF group. The researchers concluded that the TPF regimen appears to be a reasonable treatment option, but further confirmation through prospective studies is needed. [Extracted from the article]

Researchers at Ain Shams University have conducted a study on the use of a novel agent, cisplatin coupled to gold chitosan nanoparticles, in treating oral squamous cell carcinoma (OSCC) and oral epithelial cells. The study found that the nanocomposite showed promising results in inducing apoptosis, cell cycle arrest, and reactive oxygen species production in oral cancer cells, while having fewer negative effects on normal oral epithelial cells. This research provides valuable insights into potential alternative treatments for OSCC. [Extracted from the article]

Research from Wannan Medical College in China has revealed that the enzyme Carnitine palmitoyltransferase 1C (CPT1C) plays a significant role in promoting cisplatin resistance in non-small cell lung cancer (NSCLC) cells. The study suggests that understanding the molecular mechanisms behind chemotherapy resistance is crucial for improving treatment outcomes. The findings indicate that targeting CPT1C with combination therapy may offer a promising new approach to treating lung cancer. [Extracted from the article]

A study conducted at Cairo University explored the use of hydroxyapatite nanoparticles (HAP-NPs) in cancer treatment, specifically in Ehrlich solid carcinoma-bearing mice. The research found that HAP-NPs demonstrated significant anticancer activity and when combined with the chemotherapeutic drug Cisplatin, showed even higher efficacy in reducing tumor size. The study concluded that HAP-NPs can induce DNA damage and regulate apoptosis, leading to the selective elimination of tumor cells, with the combined treatment enhancing the activity of Cisplatin within the tumor tissue. [Extracted from the article]

Researchers at Southern Medical University in Guangzhou, China, have developed manganese-based nanozymes that show promise as broad-spectrum antioxidants against cisplatin-induced skeletal muscle atrophy. These nanozymes effectively scavenge reactive oxygen species (ROS) and reduce inflammation, potentially offering a therapeutic approach to combat chemotherapy-associated muscle wasting. The study highlights the potential of nanozyme-based therapeutics not only for muscle atrophy but also for other oxidative stress-related diseases. The research was supported by various funding sources and has been peer-reviewed, offering a novel strategy to address chemotherapy-induced muscle atrophy. [Extracted from the article]

Researchers from Niigata University in Japan have found that an acidic microenvironment can enhance resistance to cisplatin, a key drug used in treating advanced bladder cancer. The study showed that bladder cancer cells cultured in acidic conditions developed resistance to cisplatin, requiring higher concentrations of the drug to achieve toxicity. The research suggests that targeting the acidity of the tumor microenvironment could potentially improve bladder cancer sensitivity to cisplatin. [Extracted from the article]

Researchers at Tanta University have conducted a study on the synergistic anticancer effects of combining cisplatin with an extract from Rumex dentatus L. in treating tongue squamous cell carcinoma. The study utilized various analyses to investigate the potential of this combination treatment, which was found to be more effective in inhibiting proliferation, inducing cell cycle arrest and apoptosis, and reducing autophagy in cancer cells compared to cisplatin alone. The research suggests that this approach could offer a promising new perspective for developing more effective treatments for oral squamous cell carcinoma. [Extracted from the article]

The article discusses a clinical trial, NCT06793215, evaluating the efficacy and safety of divarasib and pembrolizumab compared to pembrolizumab and pemetrexed and carboplatin or cisplatin in treating adult participants with KRAS G12C-mutated, advanced or metastatic non-squamous non-small cell lung cancer. The study aims to assess progression-free survival, overall survival, objective response, and quality of life measures over a period of approximately 5 years. The trial is not yet recruiting participants, with an enrollment target of 600 and a completion date set for February 9, 2030. [Extracted from the article]

A study from Shahrekord University explores the potential of pyrogallol, a compound extracted from Emblica officinalis, in enhancing the sensitivity of ovarian cancer cells to cisplatin by inducing miR-15a upregulation. The research found that the combination treatment of pyrogallol and cisplatin significantly inhibited cell proliferation, colony formation, and migration, while increasing apoptosis induction. This study suggests that pyrogallol could serve as a novel therapeutic agent in ovarian cancer treatment, potentially improving chemotherapy efficacy and reducing side effects. [Extracted from the article]

Research from Xijing Hospital of Digestive Diseases has revealed that platinum drugs can increase the expression levels of CXCR4 and PD-L1 in gastric cancer. This study suggests that a combined treatment targeting these molecules may hold promise for gastric cancer patients. The findings indicate that cisplatin-induced upregulation of CXCR4 and PD-L1 is dependent on ROS-dependent pathways, offering potential implications for novel therapeutic approaches in gastric cancer. [Extracted from the article]

A clinical trial, NCT06783140, is being conducted to compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX. The trial involves two arms: one with NABPLAGEM (Nab-paclitaxel+Cisplatin+Gemcitabine) and the other with Nab-paclitaxel+gemcitabine. The study aims to assess outcomes such as overall response rate, overall survival time, progression-free survival, duration of response, CA19-9 response, and number of adverse events. The trial is not yet recruiting and is expected to be completed by March 3, 2031. [Extracted from the article]

A clinical trial, NCT06788912, is being conducted to evaluate the effectiveness of Pembrolizumab in combination with other investigational agents in treating resectable non-small cell lung cancer. The trial aims to assess the response to treatment before surgery by measuring the absence of cancer cells in tumors and lymph nodes, as well as the reduction in the number of living cancer cells in the tumor. The study involves various interventions, including neoadjuvant and adjuvant therapies, and has specific outcome measures related to pathological response, adverse events, survival rates, and surgical outcomes. [Extracted from the article]

A study conducted by Nanjing Medical University in Jiangsu, China, explored the role of asprosin in acute kidney injury induced by cisplatin. Asprosin, a peptide involved in metabolism regulation, was found to promote ferroptosis and damage in kidney cells through iron overload and lipid peroxidation. Silencing asprosin was shown to alleviate renal injury and dysfunction in cisplatin-induced acute kidney injury. This research sheds light on potential therapeutic targets for managing acute kidney injury. [Extracted from the article]

Researchers at Hashemite University in Jordan conducted a study on the cardioprotective effects of scopoletin against cisplatin-induced damage in mice. Scopoletin, a natural coumarin, showed potential in reducing oxidative stress, inflammation, and apoptosis caused by cisplatin therapy. The study found that scopoletin effectively mitigated cardiac damage, reduced inflammatory cytokines, and modulated key signaling pathways, suggesting its potential as an adjunctive therapy in cancer treatment. Further clinical investigation is warranted to explore scopoletin's benefits in countering cisplatin's adverse effects. [Extracted from the article]

Researchers at the Universidad Autonoma de Chile conducted a study on gastric cancer, focusing on the use of a combination of Maraviroc and cisplatin to inhibit tumor growth and improve survival rates in mice. The study found that the combination treatment reduced cell viability, inhibited tumor formation, and improved survival rates in mice treated with cisplatin. The researchers concluded that the Maraviroc/cisplatin combination could be a potential complementary therapy for gastric cancer. [Extracted from the article]

Researchers from Lebanese American University conducted a study on the nephroprotective effects of Lebanese Cannabis sativa extract in mice with cisplatin-induced nephrotoxicity. The study found that the cannabis extract prevented apoptosis in podocytes and improved urinary and serum parameters in mice treated with cisplatin. The research suggests that cannabis extract could be a promising approach to protect against cisplatin-induced nephrotoxicity. The study was published in the Journal of Cannabis Research. [Extracted from the article]

A recent study conducted at Harbin Medical University in Heilongjiang, China, explored the association between the overexpression of the gene HYOU1 and cisplatin resistance in patients with cervical cancer. The research identified HYOU1 as significantly upregulated in cervical cancer samples and patients who did not respond to cisplatin treatment. The study suggests that high levels of HYOU1, potentially regulated by EIF3A through m(6)A modifications, could serve as an indicator of cisplatin treatment resistance in cervical cancer patients. This research provides valuable insights into potential mechanisms underlying drug resistance in cervical cancer and highlights the importance of further investigation in this area. [Extracted from the article]

Researchers from the School of Natural Sciences in Sydney, Australia, have developed a new approach for breast cancer therapy by co-loading cisplatin and cyclophosphamide into a nanostructure called UIO-66 and functionalizing it with folic acid. The synthesized nanocarrier showed promising anticancer effects in breast cancer cell lines, reducing cell migration and invasion while enhancing apoptosis. This targeted therapy system demonstrated selective targeting and controlled drug release, potentially increasing the effectiveness of treatment for breast cancer. [Extracted from the article]

Researchers at Huntsman Cancer Hospital conducted a retrospective analysis to evaluate the dosing of gemcitabine and carboplatin in patients with cisplatin-ineligible metastatic urothelial carcinoma. The study found that many patients required dose reductions, delays, and hospitalizations while on this palliative regimen. The research suggests that starting therapy at a reduced dose may help minimize treatment interruptions, dose omissions, and side effects for these patients. This study was funded by Exelixis, Bavarian-Nordic, Clovis, and Bristol-Myers Squibb, and has been peer-reviewed. [Extracted from the article]

The University of Colorado conducted research on acute kidney injury caused by cisplatin, a common chemotherapeutic agent. The study focused on understanding the pharmacokinetics and toxicodynamics of cisplatin-induced kidney injury to predict and prevent it. The research highlighted the importance of incorporating both traditional clinical biomarkers and newer subclinical biomarkers in developing models to predict and prevent cisplatin-induced nephrotoxicity. This study was funded by various NIH institutes and was published in the Journal of Pharmacology and Experimental Therapeutics. [Extracted from the article]

A study conducted at Cangzhou Central Hospital in Hebei, China, explored the role of microsomal glutathione transferase 1 (MGST1) in cisplatin resistance of non-small cell lung cancer (NSCLC) cells. The research found that high MGST1 expression and low arachidonate lipoxygenase 5 (ALOX5) expression were associated with cisplatin resistance in NSCLC patients and cells. The study concluded that targeting MGST1 could potentially overcome cisplatin resistance in NSCLC patients, offering a new therapeutic approach. [Extracted from the article]

Researchers at Fudan University have developed a novel combination therapy involving low-dose cisplatin and a TLR7/8/9 agonist formulation to enhance antitumor immune responses. This therapy showed significant efficacy in abrogating established tumors in mouse models by promoting tertiary lymphatic structure formation and activating immune cells. The study suggests that this combination therapy has the potential to convert 'cold' tumors into 'hot' ones and induce robust antitumor immune responses in vivo. [Extracted from the article]

The article discusses how cisplatin, a common chemotherapy drug, can lead to sensory neurodegeneration and impact the quality of life of patients. The study found that transferring mitochondria from monocytes to damaged sensory neurons can prevent neurotoxicity caused by cisplatin. This process, mediated by connexin 43, shows potential as a therapeutic intervention to alleviate neuropathic pain in cancer patients undergoing chemotherapy. [Extracted from the article]

The article discusses the challenges of cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) and explores the potential of PI3K inhibitors in overcoming this resistance. The study found that PI3K inhibitors can effectively bypass Nrf2-mediated cisplatin resistance in HNSCC by inducing metabolic changes and re-sensitizing resistant cells to cisplatin. The research highlights the therapeutic potential of PI3K inhibitors, specifically gedatolisib, in combination therapies to address primary chemo-radiation failure in HNSCC. [Extracted from the article]

Researchers from Heilongjiang Bayi Agricultural University in Daqing, China, conducted a study on the protective effects of Epigallocatechin gallate (EGCG) on intestinal injury induced by Cisplatin (CIS) in rats. The study found that EGCG alleviated CIS-induced intestinal damage, with the 40 mg/kg dose showing the most significant protective effect. EGCG treatment influenced the gut microbiota, metabolic pathways, and inhibited proteins associated with autophagy and the NRF2/Keap1 signaling pathway. The research concluded that EGCG ameliorates CIS-induced hepatoenteric toxicity by regulating intestinal flora and targeting the Nrf2/Keap1 signal axis. [Extracted from the article]

Researchers at Jilin Agricultural University in China have discovered that chiisanoside derivatives from Acanthopanax sessiliflorus can activate autophagy through the LRP6/GSK3b axis, inhibiting oxidative stress and potentially counteracting cisplatin-induced ototoxicity. Compound 19, a derivative of chiisanoside, showed significant protective activity against cisplatin-induced ototoxicity in cell and mouse models. The study suggests that compound 19 could prevent ototoxicity by activating autophagy, offering a new approach to treating cisplatin-induced ototoxicity and sensorineural hearing loss. [Extracted from the article]

Researchers from the Second Hospital of Lanzhou University have identified that overactivation of SRC is associated with cisplatin resistance in bladder cancer. SRC activates pathways that increase nucleotide synthesis and NADPH production, protecting cancer cells from cisplatin-induced DNA damage. Targeting SRC with inhibitors like eCF506 shows promise in overcoming cisplatin resistance and enhancing sensitivity to treatment. This study provides new insights for combination therapy in bladder cancer. [Extracted from the article]

Researchers at CHA Bundang Medical Center in South Korea conducted a study on the effects of cisplatin therapy on renal injury in mice. They administered cisplatin and lipopolysaccharide to mice and observed significant renal damage, including tubular damage and fibrosis. The study concluded that co-administration of cisplatin and LPS resulted in a distinct renal injury model in mice. This research provides valuable insights into the potential nephrotoxic side effects of cisplatin therapy. [Extracted from the article]

A study conducted at Nagoya City University focused on predicting cisplatin-induced acute kidney injury (Cis-AKI) using an interpretable machine learning model and electronic medical record information. The research included 1253 hospitalized patients who received cisplatin chemotherapy, with 9.5% developing Cis-AKI. The study found that the concomitant use of intravenous magnesium preparations was negatively correlated with Cis-AKI, suggesting the potential benefits of magnesium in preventing AKI. The model developed in the study showed promise in predicting Cis-AKI early, potentially aiding in its avoidance. [Extracted from the article]

Researchers have submitted a patent application for a method to alleviate resistance to chemotherapy in patients with solid tumors, including lung cancer. The method involves administering a composition that targets the interaction between integrin b4 and paxillin, potentially overcoming resistance to platinum-based chemotherapy drugs like cisplatin. This innovation aims to expand therapeutic options for patients facing chemoresistance, offering a promising approach to improve cancer treatment outcomes. [Extracted from the article]

Researchers at Baqiyatallah University of Medical Sciences in Tehran, Iran, have identified a novel mechanism of cisplatin resistance in ovarian cancer involving the long non-coding RNA LINC02381. The study reveals that interleukin-12 (IL-12) induces Wnt signaling, leading to increased expression of LINC02381, which in turn upregulates ATP-binding cassette (ABC) transporters, reducing cisplatin concentration in cancer cells. Targeting this IL-12/Wnt/TCF7/LINC02381 axis may offer promising therapeutic strategies to overcome chemotherapy resistance in ovarian cancer. Further research is needed to validate these mechanisms and explore potential interventions to disrupt this feedback loop. [Extracted from the article]

A recent study conducted at Asan Medical Center in Korea examined the efficacy and toxicity of paclitaxel-cisplatin-bevacizumab as a first-line treatment for platinum-naive primary stage IVB cervical cancer. The study included 61 patients with a median age of 56 years, who received a median of 9 cycles of treatment. The research found that a reduction rate of 40% in cervical mass size during treatment could be a potential prognostic factor for progression-free survival in these patients. The study concluded that paclitaxel-cisplatin-bevacizumab is effective and well-tolerated for this type of cancer. [Extracted from the article]

Researchers from Charite University Hospital and School of Medicine have found that high Ano1 expression is a key driver of resistance to radiation and cisplatin in HPV-negative head and neck squamous cell carcinoma. The study analyzed the impact of Cyclin D1 and Ano1 overexpression on survival and identified potential treatment combinations for high-risk patient groups. The findings suggest that Copanlisib and afatinib could be promising candidates for combination therapy in 11q13-amplified HNSCC tumors. [Extracted from the article]

A study conducted at the Cancer Institute Hospital in Tokyo, Japan, explored the relevance of lymph-node ratio (LNR) as a risk factor for recurrence in patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemotherapy. The research found that a higher LNR was associated with worse disease-free survival rates and increased recurrence following treatment with docetaxel, cisplatin, and 5-fluorouracil. This study provides valuable insights into the clinical utility of LNR in predicting outcomes for patients with ESCC. [Extracted from the article]

A randomized phase II trial, NCT06770582, compares pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil, or mitomycin-C and radiation therapy for non-muscle invasive bladder cancer treatment. The trial aims to evaluate bladder-intact event-free survival, complete response by cystoscopy, disease-free survival, local-regional control, metastasis-free survival, overall survival, and quality of life. Patients will be followed up for up to 5 years to assess outcomes and adverse events. The trial is not yet recruiting and aims to enroll 160 participants by February 1, 2032. [Extracted from the article]